www.finanznachrichten.de · · DE
68613798 abbott secures ce mark for world s first dual glucose ketone sensing technology for people with diabetes 008
Topic context
This topic has been covered 306289 times in the last 7 days across our monitored publishers.
The full article is on the original publisher site.
AI insight
AI-generatedAbbott's CE Mark approval for dual glucose-ketone monitoring technology creates a new product category in diabetes management. The commercial mechanism is product innovation and regulatory clearance, expanding Abbott's continuous glucose monitoring (CGM) franchise. Revenue growth expected from new device sales and consumables. Competitors (Dexcom, Medtronic) may face substitute pressure if Abbott captures market share. Impact is global but initial launch in Europe.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Abbott received CE Mark approval for Libre Duo and Libre Duo 10 Day systems.
- These are the world's first dual glucose and ketone monitoring biowearables.
- Systems measure glucose and ketone levels every minute.
- DKA rates have increased by approximately 55% over the past decade.
- Launch in select European countries later in 2026.
Related stories
countercurrents.org
When the Obscene Erupts Caste Violence and the Schizophrenic Modernity of India
premiumtimesng.com
883270 32 african countries now spend more on debt servicing than healthcare experts
skepticalscience.com
New Research 2026 22
siliconindia.com
Indiacanada Trade Corridor Powers AI and Semiconductor Growth Nid 240830 Cid 1
mirror.co.uk